- Senate passes Drug Quality and Security Act
- Roxane Labs' generic prostate drug gets tentative approval from FDA
- FDA approves Plan B One-Step OTC switch
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Mylan looks to become first to market generic ulcerative proctitis drug
NEW YORK — Mylan will be banned temporarily from launching a generic drug for acne pending a federal court's decision whether or not to bar it, according to published reports.
According to Bloomberg, the U.S. District Court for the District of Delaware ruled that Mylan violated 1-of-4 patents covering the acne drug Oracea (doxycycline), sold by Galderma Labs. Galderma, New York University and the Research Foundation of the State University of New York sued Mylan for patent infringement related to the drug in 2009. The court will wait to decide whether to bar Mylan from launching.
Patents covering Oracea are scheduled to expire between Aug. 30, 2016, and Dec. 19, 2027, according to Food and Drug Administration records.